REBEC

Go to main content [1]
Go to main menu [2]
Enable hight contrast [3]

-

-

-

-

-

Public trial

The effect of physical exercise on quality of life, mental health and continuity of chemotherapy sessions in individuals with cancer undergoing online intervention: a randomized clinical study

Date of registration: 12/06/2021 ^(mm/dd/yyyy)
Last approval date : 12/06/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Assessment of Locked Nose Improvement in patients who received a Nasal Implant

Date of registration: 12/06/2021 ^(mm/dd/yyyy)
Last approval date : 12/06/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Observational

Pilates and Dance classes for patients diagnosed with Head and Neck Cancer in treatment and post-treatment.

Date of registration: 12/05/2021 ^(mm/dd/yyyy)
Last approval date : 12/05/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

The Effect of Osteopathy in Patients with Fibromyalgia.

Date of registration: 12/03/2021 ^(mm/dd/yyyy)
Last approval date : 12/03/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Quality of life questionnaire related to symptoms of gastroesophageal reflux disease.

Date of registration: 12/03/2021 ^(mm/dd/yyyy)
Last approval date : 12/03/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Impact of a Physical Exercise Program on Muscle, Lung, Quality of Life, Sleep, and Mental Health of Recovered Covid-19 Patients

Date of registration: 12/03/2021 ^(mm/dd/yyyy)
Last approval date : 12/03/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effects to the nervous system of Passive Technique on the Chest in patients with High Blood Pressure, immediate result and after 1 week

Date of registration: 12/03/2021 ^(mm/dd/yyyy)
Last approval date : 12/03/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Bright light influence on blood vessel response to hand exercise

Date of registration: 12/02/2021 ^(mm/dd/yyyy)
Last approval date : 12/02/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Analysis of the benefits of Electrical Stimulation on the memory of healthy elderly people

Date of registration: 12/02/2021 ^(mm/dd/yyyy)
Last approval date : 12/02/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Measurement of breathing by skin electrodes using electrical impedance tomography

Date of registration: 12/02/2021 ^(mm/dd/yyyy)
Last approval date : 12/02/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Observational

Analysis of physical activity and educational program on the burden and quality of life of caregivers of people with Amyotrophic Lateral Sclerosis.

Date of registration: 12/02/2021 ^(mm/dd/yyyy)
Last approval date : 12/02/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Assessment of quality of life pain and mouth opening after wisdom tooth extraction using different oral dexamethasone protocols

Date of registration: 12/02/2021 ^(mm/dd/yyyy)
Last approval date : 12/02/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effect of Abdominal Exercises on scapular positioning and shoulder performance in people with Shoulder Pain and Altered Scapulae

Date of registration: 12/02/2021 ^(mm/dd/yyyy)
Last approval date : 12/02/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Air-volume measurement during newborns respiration while breathing calmly using electrical impedance tomography

Date of registration: 12/01/2021 ^(mm/dd/yyyy)
Last approval date : 12/01/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Observational

Individualized Sports Mouthguards: Evaluation of Muscle Effects and Sports Performance in Children

Date of registration: 11/30/2021 ^(mm/dd/yyyy)
Last approval date : 11/30/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Ocurrence of temporomandibular disorder symptoms with the use of orthodontic aligners

Date of registration: 11/29/2021 ^(mm/dd/yyyy)
Last approval date : 11/29/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Osteopathy in the treatment of reflux

Date of registration: 11/29/2021 ^(mm/dd/yyyy)
Last approval date : 11/29/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Assessment of left ventricular function using imaging exam

Date of registration: 11/29/2021 ^(mm/dd/yyyy)
Last approval date : 11/29/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Observational

Injections for back pain

Date of registration: 11/24/2021 ^(mm/dd/yyyy)
Last approval date : 11/24/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Study comparing the efficacy of fosfomycin and ciprofloxacin antibiotics in the antibiotic prophylaxis of transrectal prostate biopsy

Date of registration: 11/23/2021 ^(mm/dd/yyyy)
Last approval date : 11/23/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Username/Password

News

10/03/2025

Innovation in healthcare roundup: HCA Healthcare, the Allergy Centre of Excellence, Fujifilm and Optegra

10/03/2025 | Adrian Murdoch | Heathcare Today

https://healthcaretoday.com/article/innovation-in-healthcare-roundup-hca-healthcare-the-allergy-centre-of-excellence-fujifilm-and-optegra

The latest innovations in healthcare, including tumour-infiltrating lymphocyte therapy, allergies, cancer support and drop-free cataract treatment.
HCA Healthcare trials tumour-infiltrating lymphocyte therapy
US-owned private hospital operator HCA Healthcare will treat a metastatic lung cancer patient with tumour-infiltrating lymphocyte (TIL) therapy for the first time as part of a clinical trial at its research arm, Sarah Cannon Research Institute UK.

TIL therapy leverages the body’s own immune cells called tumour-infiltrating lymphocytes, which are naturally present within tumours and trained to target cancer cells. In February 2024, the Food and Drug Administration (FDA) approved TIL therapy as the first cellular therapy to treat solid tumours, initially for melanoma treatment under the name Lifileucel (Amtagvi).

At Sarah Cannon Research Institute UK, clinical trials are now exploring TIL therapy’s efficacy in advanced and metastatic non-small-cell lung cancer. The patient was referred from the NHS for participation in this groundbreaking clinical trial.

“TIL therapy represents a potential new treatment option for patients whose advanced cancer has become resistant to other therapies,” said Anja Williams, consultant medical oncologist at Sarah Cannon Research Institute UK. “By using the patient’s own immune cells that are already trained to target their specific cancer, we’re essentially harnessing and enhancing the power of their immune system to target the disease,” she continued.

First…

10/03/2025
How Government Shutdowns Set Back Clinical Trials

10/03/2025 | Denise N. Bronner | Clinical Leader

https://www.clinicalleader.com/doc/how-government-shutdowns-set-back-clinical-trials-0001

When the federal government shuts down, news coverage tends to spotlight furloughed workers, frozen paychecks, or the political drama playing out in Washington. What gets less attention is how these lapses stall the engine of scientific progress. For clinical research, even a brief shutdown can trigger cascading consequences: disrupted operations, wavering patient participation, delayed approvals, and setbacks for urgently needed therapeutics.

Clinical research thrives on continuity. It is built on tightly orchestrated timelines, fragile patient trust, and a steady flow of regulatory and financial resources. When that continuity is interrupted, the ripple effects extend far beyond missed deadlines. They reach the lives of patients who depend on trials for care and the future of therapies waiting to move from pipeline to practice.

Regulatory Bottlenecks & Uncertainty
The FDA sits at the center of clinical research, reviewing new drug applications, monitoring safety, and ensuring compliance. A shutdown leaves the agency with only a skeleton crew. Historically, about one-third of FDA staff have been furloughed during extended shutdowns, forcing the Agency to pause most routine operations. New drug and device submissions may be accepted, but reviews stall. Site inspections and audits, critical for moving programs forward, are postponed. And sponsors often find their regulatory queries met with silence.

These delays may seem procedural, but they create real-world consequences. A biotech preparing to launch a pivotal trial might suddenly find its timeline upended. A CRO monitoring multiple sites may have to cancel visits, raising questions…

10/01/2025
Enactment of Law No. 14,874 ushers in a new era of clinical research

09/29/2025 | Fernando de Rezende Francisco | Medicina S/A

https://medicinasa.com.br/sancao-lei-14-874-2024/

Brazil has begun a new chapter in Clinical Research with the enactment of Law No. 14,874/2024, which establishes a robust and modern regulatory framework in line with international best practices. More than just updating standards, the law creates conditions to expand the population's access to studies that bring innovation, new therapies, and a better quality of life.

Although the legislative process took almost a decade, the most recent stage of this process was marked by the leading role played by the Ministry of Health, through the Secretariat of Science, Technology, Innovation, and Health Complex (SECTICS) and the Department of Science and Technology (DECIT). In recent months, these areas have taken the lead on the agenda, competently and dialogically conducting the process that will culminate in the beginning of the regulation of the law and the reorganization of the ethical research system.

Despite its enormous potential, Brazil participates in just over 1% of global clinical studies, according to ClinicalTrials.gov. This means less investment, less access to cutting-edge technologies, and fewer opportunities for patients. Law No. 14,874/2024 paves the way for changing this scenario, and the recent actions of the Ministry of Health are decisive in consolidating these transformations.

The movement to draft a law for this area gained momentum in 2014 when Afonso Celso Haas, a businessman from Rio Grande do Sul diagnosed with advanced lung cancer, found a chance to prolong his life in a clinical trial. The experimental treatment not only gave him five additional years with his family, but also turned him into a symbol of the fight for the modernization of the sector.

Inspired by his story, doctors, lawmakers, organizations, and civil society…

10/01/2025
Law 14.874/24: a new perspective for clinical research in Brazil

10/01/2025 | Eurico Bitencourt Neto, Brunello Stancioli | Jota

https://www.jota.info/opiniao-e-analise/artigos/lei-14-874-24-uma-nova-perspectiva-para-a-pesquisa-clinica-no-brasil

Legislation is welcome and represents a bioethical and administrative milestone for Brazilian research

Improvements in the health, well-being, and productivity of contemporary societies are largely linked to advances in biomedical research and the improvements they bring to collective and individual health. In an era marked by exponential production of information and knowledge and, at the same time, by growing uncertainty and risk, biomedical sciences play a central role as a tool that saves lives and prevents disease in a world that still grapples with profound inequalities, thus serving as an important instrument of social justice.

In this context of undeniable relevance, the progress of biomedical research involves a double ethical challenge. On the one hand, preventing or hindering scientific research means hindering prophylaxis, cure, and prevention for countless diseases, hindering the achievement of better health conditions and adequate care for those facing various causes of suffering. On the other hand, clinical research involves the participation of volunteers who agree to subject themselves to certain risks in order for scientific progress to be achieved, which requires a protection system that ensures the preservation of their fundamental rights of personality.

Ensuring the ethics of research and the safety and interests of research participants is fundamental in this process, as they are the key to the tests that culminate in scientific advancement. However, until last year, Brazil offered very fragile legal guarantees to research participants.

Research ethics standards in Brazil…

09/30/2025
Age Diversity In Clinical Trials: Considerations For Improving Older Adult Representation

09/30/2025 | Nick Charron and Hannah Yang | Clinical Leader

https://www.clinicalleader.com/doc/age-diversity-in-clinical-trials-considerations-for-improving-older-adult-representation-0001

The share of the U.S. population aged 65 and older grew to 18% in 2024,1 now outnumbering children in nearly half of the country's counties. These demographic shifts are expected to continue, with estimates stating that the global population above 60 will double by 2050.2

It’s crucial to understand how these trends impact clinical trials,3 where older adults have historically been underrepresented. For several large oncology indications, the enrollment-to-incidence ratio (EIR) is only 25% for those above 70,4 revealing a significant discrepancy in inclusion.

Without prioritizing DEI, research findings aren’t fully generalizable5 to this key demographic, limiting the applicability of trials. In this piece, we dive into the importance of age diversity in clinical trials, breaking down innovative methods to redesign clinical trials and better engage older populations in the U.S.

Implications Of Underrepresenting Older Adults In Clinical Trials
Despite the shifting demographics of the U.S. population, only 50%6 of clinical trials specifically enroll patients under the age of 65, and 8% of trials enroll patients 80 and older. Many clinical trials also exclude older adults with comorbidities,7 further limiting their relevance to real-world populations.

While it’s true that comorbidities can complicate trial results and risk jeopardizing approval of a viable therapy, overly stringent inclusion/exclusion (I/E) criteria unnecessarily restrict participation. This exclusion creates a gap in data8 on efficacy and safety of treatments…

Total de Ensaios Clínicos 16962.

Existem 8357 ensaios clínicos registrados.

Existem 4701 ensaios clínicos recrutando.

Existem 241 ensaios clínicos em análise.

Existem 5772 ensaios clínicos em rascunho.

cadastre um novo usuário

notícias

sobre

ajuda

contato

equipe

links úteis

glossário